MabSpace is developing antibody-based treatments to fight off tumours that are resistant to immune system-based therapies.
China-based biotechnology company MabSpace Biosciences closed its series A round at $15m on Wednesday with Lilly Asia Ventures, the local corporate venturing outfit of pharmaceutical firm Eli Lilly, as sole backer.
MabSpace is working on antibody-based therapies for tumours which have shown resistance to T cell checkpoint monotherapy, an approach that uses the body’s own immune system to fight cancer.
The company will now advance its current candidates into clinical trials and expand its pipeline. Stephen Lin, principal of Lilly…